Cellular and Molecular Pharmacology Discipline
Center for Neurobiology of Stress Resilience and Psychiatric Disorders
Dr. Joanna Dabrowska earned a PharmD degree in 2000 from Wroclaw Medical University, School of Pharmacy, and a PhD in Neuropharmacology in 2006 from the Medical University of Silesia in Poland. She continued her postdoctoral training at Emory University in Atlanta and in 2014, she joined the faculty of the Chicago Medical School as an Assistant Professor of cellular and molecular pharmacology and neuroscience. She is now an Associate Professor of cellular and molecular pharmacology and faculty member of the Center for Neurobiology of Stress Resilience and Psychiatric Disorders. Joanna’s research has been continuously supported by the National Institute of Mental Health, NIH (K99/R00 MH096746, R01 MH113007, 2R01 MH113007) since 2014.
Research Overview
Our lab has a long-standing interest in the neurobiology of stress-related psychiatric disorders including post-traumatic stress disorder (PTSD) and generalized anxiety disorder (GAD). The hallmarks of PTSD in humans include hyperarousal, inability to properly discriminate between stimuli that predict danger vs. stimuli that predict safety, and higher fear reactivity to unpredictable vs. predictable threats. To better understand the neurobiology of adaptive vs. maladaptive fear processing, we use rodent models of defensive behaviors, such as fear- and anxiety-potentiated startle (FPS and APS, respectively) in male and female rats. The interaction of many brain regions contributes to processing of fear memories. Our lab investigates the functional neuroanatomy of the extended amygdala, which comprises the bed nucleus of the stria terminalis (BNST) and the central amygdala (CeA), and their respective contributions to processing of unpredictable vs. predictable threats. Within this neurocircuitry, we are particularly interested in the neuromodulation by peptides (oxytocin, OT; vasopressin, AVP; corticotropin-releasing factor, CRF), their impact on specific neuronal populations and their unique roles in the regulation of the extended amygdala activity and fear behaviors. We utilize in vitro slice electrophysiology combined with optogenetics, neuronal tract tracing and immunofluorescence techniques, chemogenetics in transgenic rat models (OT-receptor-Cre, CRF-Cre, AVP-Cre), and behavioral testing (FPS, APS) to understand the cellular mechanisms of these neuropeptides’ actions in the extended amygdala. This research has a unique translational validity to anxiety disorders since human brain imaging has shown increased BNST activity in the conditions of uncertainty and hypervigilant threat monitoring and BNST hyperactivity in individuals with PTSD and GAD.
Current research projects:
Dr. Fulvia Berton, PhD, Research Specialist
I work in the electrophysiological laboratory using rat brain slice preparation. I use the combination of patch clamp electrophysiological recordings with neuronal tract tracing and/or optogenetic stimulation in wild-type and transgenic rats to identify the role of Oxytocin (OT) or Vasopressin (AVP) on neuronal activity in the bed nucleus of the stria terminalis (BNST).
Rachel Chudoba, BSc, PhD Candidate
I study the role of neurons producing corticotropin-releasing factor (CRF) in the BNST in variety of defensive behaviors in males and female rats using chemogenetics in CRF-Cre transgenic rats (Cre-recombinase under CRF promoter, originally developed by Dr. Bob Messing, UT Austin). I’m complementing this work with in vitro electrophysiology recordings to understand the intrinsic membrane properties, synaptic activity, and intrinsic connectivity of CRF neurons in the BNST in male and female rats.
Dr. Walter Francesconi, PhD, Senior Research Associate
I am an electrophysiologist with an expertise and extensive experience in recording neuronal activity of the BNST, a brain region involved in addiction, fear, and anxiety-behaviors. Using a whole-cell patch clamp recordings from different types of electrophysiologically defined BNST neurons (Type I-III), in combination with optogenetic tools to evoke peptide release, I investigate the functional intrinsic organization of this neural hub and the neuromodulatory role of hypothalamic oxytocin and vasopressin peptidergic inputs on the BNST activity.
Lorena Monroy, Lake Forest College student, 2023-24 Bartram Research Scholar
I study the role of AVP neurons in the suprachiasmatic nucleus of the hypothalamus (SCN) in the regulation of defensive behaviors such as fear- and anxiety-related behaviors in male and female rats. I use chemogenetic techniques in AVP-Cre rats (Cre-recombinase under AVP promoter, originally created by Dr. Valery Grinevich, University of Heidelberg, Germany) to determine how the AVP-SCN neurons contribute to changing levels of defensive behaviors along the circadian rhythms.
Dr. Valentina Olivera-Pasilio, PhD, Postdoctoral Fellow
My project focuses on the role of oxytocin receptors and oxytocin receptors-expressing neurons in the BNST in the modulation of fear and anxiety-like responses. I use chemogenetics in OTR-Cre transgenic rats (Cre-recombinase under OTR promoter, originally created by Dr. Valery Grinevich, University of Heidelberg, Germany) to understand the role of OTR-neurons in the BNST in modulating these behaviors. I am also interested in studying the role of the projection neurons from the BNST to the central amygdala (CeA) in fear and anxiety, and how oxytocin receptors modulate activity of these projection neurons. Lastly, my work investigates sex and strain differences in fear-potentiated startle responses.
Susan H. Olson, BSc, Lab Manager
I work with lab personnel to ensure smooth and efficient lab operations. I make sure all safety protocols are followed at the bench and in animal care, I train individuals in the use and care of animals in research as well as various surgical techniques in order to help them progress in their research projects. I also specialize in the hypothalamic stereotaxic surgeries and help with implementation of circadian rhythms into the research projects.
Fear-Conditioning to Unpredictable Threats Reveals Sex and Strain Differences in Rat Fear-Potentiated Startle (FPS). Neuroscience. (2023) 530:108-132.
From recent advances in underlying neurocircuitry of fear and anxiety to promising pharmacotherapies for PTSD: The saga of heart, sex and the developing brain Neuropharmacology. (2023) 232:109529.
Distinct populations of corticotropin-releasing factor (CRF) neurons mediate divergent yet complementary defensive behaviors in response to a threat. J. Neuropharmacology. (2023) 228:109461.
Dabrowska J. Should I Freeze or Should I Go? The Ventral Subiculum → Bed Nucleus of the Stria Terminalis Neurons Yield the Right-of-way. Neuroscience. (2022) 502:117-118.
Oxytocin excites BNST interneurons and inhibits BNST output neurons to the central amygdala. Neuropharmacology. (2021) 192:108601.
Limbic Neuropeptidergic Modulators of Emotion and Their Therapeutic Potential for Anxiety and Post-Traumatic Stress Disorder. J Neurosci. (2021) 41:901-910.
Oxytocin Promotes Accurate Fear Discrimination and Adaptive Defensive Behaviors. Front Neurosci. (2020) 14:583878.
Neuronal diversity of the amygdala and the bed nucleus of the stria terminalis. In: Handbook of Amygdala Structure and Function; A. Rosenkranz and J. Urban (Eds.); Handbook of Behavioral Neuroscience Series, Vol. 26; Academic Press/Elsevier, London, 2020.
Oxytocin receptors in the dorsolateral bed nucleus of the stria terminalis (BNST) bias fear learning toward temporally predictable cued fear. Transl Psychiatry. (2019) 9:140.
Oxytocin facilitates adaptive fear and attenuates anxiety responses in animal models and human studies-potential interaction with the corticotropin-releasing factor (CRF) system in the bed nucleus of the stria terminalis (BNST). Cell Tissue Res. (2019) 375:143-172.
Corticotropin-Releasing Factor Receptors Modulate Oxytocin Release in the Dorsolateral Bed Nucleus of the Stria Terminalis (BNST) in Male Rats. Front Neurosci. (2018) 12:183.
Repeated shock stress facilitates basolateral amygdala synaptic plasticity through decreased cAMP-specific phosphodiesterase type IV (PDE4) expression. Brain Struct Funct. (2017) 223:1731-1745.
Oxytocin receptor neurotransmission in the dorsolateral bed nucleus of the stria terminalis facilitates the acquisition of cued fear in the fear-potentiated startle paradigm in rats. Neuropharmacology. (2017) 121:130-139.
Targeting Corticotropin-Releasing Factor Projections from the Oval Nucleus of the Bed Nucleus of the Stria Terminalis Using Cell-Type Specific Neuronal Tracing Studies in Mouse and Rat Brain. J Neuroendocrinol. (2016) Dec;28(12). doi: 10.1111/jne.12442.
Oxytocin in the nucleus accumbens shell reverses CRFR2-evoked passive stress-coping after partner loss in monogamous male prairie voles. Psychoneuroendocrinology (2016) 64:66-78.
Striatal-enriched protein tyrosine phosphatase - STEPs toward understanding chronic stress-induced activation of CRF neurons in the rat BNST. Biological Psychiatry (2013) 74:817-26.
Central CRF neurons are not created equal: Phenotypic differences in CRF-containing neurons of the rat paraventricular hypothalamus and the bed nucleus of the stria terminalis. Frontiers in Neuroscience (2013) 7:156.
Distribution and Functional Expression of Kv4 Family α Subunits and Associated KChIP β Subunits in the Bed Nucleus of the Stria Terminalis. Journal of Comparative Neurology (2014) 522:609-25.
Thy1-expressing neurons in the basolateral amygdala may mediate fear inhibition. Journal of Neuroscience (2013) 33:10396-404.
Differential distribution of serotonin receptor subtypes in BNST(ALG) neurons: Modulation by unpredictable shock stress. Neuroscience (2012) 225C:9-21.
Presynaptic Muscarinic M2 Receptors Modulate Glutamatergic Transmission in the Bed Nucleus of the Stria Terminalis. Neuropharmacology (2012) 62:1671-83.
Synergistic Activation of Dopamine D1 and TrkB Receptors Mediate Gain Control of Synaptic Plasticity in the Basolateral Amygdala. PLoS One. (2011) 6(10):e26065.
Neuroanatomical evidence for reciprocal regulation of the corticotrophin-releasing factor and oxytocin systems in the hypothalamus and the bed nucleus of the stria terminalis: Implications for balancing stress and affect. Psychoneuroendocrinology (2011) 36:1312-26.
A transcriptomic analysis of type I-III neurons in the bed nucleus of the stria terminalis Mol Cell Neurosci (2011) 46:699-709.
Expression and distribution of Kv4 potassium channel subunits and potassium channel interacting proteins in subpopulations of interneurons in the basolateral amygdala. Neuroscience (2010) 171:721-33.
A novel transgenic mouse for gene-targeting within cells that express corticotropin-releasing factor. Biological Psychiatry (2010) 67:1212-6.
The response of neurons in the bed nucleus of the stria terminalis to serotonin: implications for anxiety. Prog Neuropsychopharmacol Biol Psychiatry (2009) 33:1309-20.
Reactivity of 5-HT1A receptor in adult rats after neonatal noradrenergic neurons’ lesion – Implications for antidepressant-like action. Brain Res. (2008) 1239:66-76.
Histamine H(3) receptor ligands modulate L-dopa-evoked behavioral responses and L-dopa derived extracellular dopamine in dopamine-denervated rat striatum. Neurotox Res. (2008) 13:231-40.
Amphetamine and mCPP effects on dopamine and serotonin striatal in vivo microdialysates in an animal model of hyperactivity. Neurotox Res (2007) 11:131-44.
Desensitization of 5-HT1A autoreceptors induced by neonatal DSP-4 treatment. Eur Neuropsychopharmacol (2007) 17:129-37.
Stereoselectivity of 8-OH-DPAT toward the serotonin 5- HT1A receptor: biochemical and molecular modeling study. Biochem Pharmacol (2006) 72:498-511.
Histamine H3 agonist- and histamine H3 antagonist-evoked vacuous chewing occurs in the absence of change in microdialysate dopamine levels. Eur J Pharmacol (2006) 552:46-54.
Degeneration of dopaminergic mesocortical neurons and activation of compensatory processes induced by a long-term paraquat administration in rats; implication for Parkinson’s disease. Neuroscience (2006) 141:2155-2165.
Prenatal cadmium and ethanol increase amphetamine-evoked dopamine release in rat striatum. Neurotoxicology and Teratology (2006) 28:563-72.
Molecular mechanisms of levodopa action in animal models of Parkinson's disease. Neurol Neurochir Pol. (2006) 40:517-25.
A slowly developing dysfunction of dopaminergic nigrostriatal neurons induced by long-term paraquat administration in rats: an animal model of preclinical stages of Parkinson's disease? Eur J Neurosci (2005) 22:1294-1304.
Influence of paraquat on dopaminergic transporter in the rat brain. Pharmacol Rep (2005) 57:330-335.
Central effects of nafadotride, a dopamine D3 receptor antagonist in rats. Comparison with haloperidol and clozapine. Pharmacol Rep (2005) 57:161-169.